<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        42-355-07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Fluorouracil Ebewe  5000mg/100ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUOROURACIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        98.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>5-Fluorouracil Ebewe contains the active substance fluorouracil. It is an anti-cancer medicine.</p><p>&nbsp;</p><p>5-Fluorouracil Ebewe is used to treat many common cancers (malignant tumours), particularly cancers of the large bowel, stomach, pancreas, breast, head and neck, and neck of the womb (cervix). It can be used in combination with other anti-cancer medicines and radiotherapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use 5-Fluorouracil Ebewe</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to fluorouracil or any of the other ingredients listed in section 6.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your blood count has changed significantly or you suffer from bleeding (haemorrhage)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from severe liver and/or kidney impairment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have serious infections (e.g. herpes zoster, chickenpox)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your tumour is non-malignant</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have inflammation of the oral mucosa (stomatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ulcers in your mouth or the gastrointestinal tract (ulcerations)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in inflammation of the small intestine (enteritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are very much weakened by long illness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your bone marrow has been damaged by other therapies (including radiotherapy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you take brivudine as treatment for chickenpox or herpes zoster, also called shingles.<br />Fluorouracil together with brivudine may substantially intensify side effects of 5-Fluorouracil Ebewe. This interaction can be fatal. Therefore, you must not use this medicine with fluorouracil chemotherapy. You can start chemotherapy with 5-fluorouracil at the earliest 4 weeks after completing herpes zoster therapy with brivudine. If you are being treated for a herpes zoster infection or have recently been treated, please tell your doctor about the medicine you have taken.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or breast-feeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with dihydropyrimidine dehydrogenase (DPD) deficiency, usual 5-fluorouracil doses cause intensified side effects. If severe side effects occur, a screening of DPD activity can be recommended. Patients with DPD deficiency must not be treated with 5-fluorouracil.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaccinations with live vaccines (e.g. measles, mumps, rubella) must not be performed during the treatment with 5-fluorouracil. All contact with poliomyelitis vaccines should be avoided.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>5-Fluorouracil Ebewe should only be prescribed by doctors with adequate experience in the treatment of the particular disease with fluorouracil.</p><p>Talk to your doctor before using 5-Fluorouracil Ebewe</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the number of cells in your blood becomes too low (you will have blood tests to establish this)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your kidneys</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your liver, including jaundice (yellowing of the skin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your heart. Tell your doctor if you experience any chest pain during treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; know that you have a partial deficiency in the activity of the enzyme dihydropyrimidine dehydrogenase (DPD)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had high-dose pelvic radiation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the following side effects appear: inflammation of the mucous membranes inside the mouth or other mucous membranes, diarrhoea, bleeding from the gastrointestinal tract, or bleeding at any other sites</p><p>&nbsp;</p><p><u>DPD deficiency: </u></p><p>DPD deficiency is a rare condition present at birth that is not usually associated with health problems unless you receive certain medicines. If you have an unrecognised DPD deficiency and take 5-flourouracil, you are at an increased risk of acute and early onset of severe forms of the side effects listed under section 4, &ldquo;Possible side effects&rdquo;. If you have any concerns regarding these side effects, or if you notice any additional side effects not listed in this leaflet (see section 4, &ldquo;Possible side effects&rdquo;), talk to your doctor immediately.</p><p>Talk to your doctor immediately if you notice any of the following signs or symptoms: appearance of confusion, disorientation, or other changes of the mental state, balance or coordination disorders, visual disturbances. These could be signs of an encephalopathy (pathological brain conditions) that may lead to coma and death if left untreated.</p><p>&nbsp;</p><p><u>Children and adolescents</u></p><p>There is insufficient experience of the use of 5-fluorouracil in children and adolescents.</p><p>&nbsp;</p><p><strong>Other medicines and 5-Fluorouracil Ebewe</strong></p><p>Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines.</p><p>&nbsp;</p><p>Remember to notify your doctor about the treatment with fluorouracil, if the doctor prescribes you another medication during treatment.</p><p>&nbsp;</p><p><strong>You must not take brivudine (an anti-viral medicine used to treat shingles or chickenpox) at the same time as 5-fluorouracil treatment (including during any rest periods when you are not taking any 5-fluorouracil tablets).</strong></p><p><strong>If you have taken brivudine you must wait for at least 4 weeks after stopping brivudine before starting to take 5-fluorouracil. See also the section &ldquo;Do not use 5-Fluorouracil Ebewe&rdquo;.</strong></p><p><strong>&nbsp;</strong></p><p>It is particularly important to inform your doctor if you are taking/using the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate, vinorelbine, cyclophosphamide, mitomycin C, tamoxifen (anti-cancer medicines)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metronidazole (an antibiotic)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium leucovorin (also called calcium folinate &ndash; used to reduce the harmful effects of anti-cancer medicines)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allopurinol (used to treat gout)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cimetidine (used to treat gastric ulcers)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin (used to treat blood clots)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cisplatin (an anti-cancer medicine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin (used to control epilepsy/seizures and arrhythmias)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaccines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; levamisole (medicine used to treat worm infection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chlordiazepoxide (a sedative), disulfiram (in case of alcohol addiction), griseofulvin (for treatment of fungal infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aminophenazone (analgesics), phenylbutazone (antirheumatics) and sulphonamide (antibiotics)</p><p>The above medicines affect the effect of fluorouracil.</p><p>Calcium folinate must not be mixed in the same IV injection or infusion as the 5-fluorouracil.</p><p>&nbsp;</p><p>Fluorouracil can increase any radiotherapy-induced toxic effect on the skin.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>Fluorouracil must not be given during pregnancy.</p><p>&nbsp;</p><p>As a woman of childbearing age, you must use an effective method of contraception while taking this medicine and at least 6 months afterwards. Should you become pregnant during your treatment despite this, you must inform your doctor and should use genetic counselling.</p><p>&nbsp;</p><p>Since it is not known whether fluorouracil passes into breast milk, breast-feeding must be discontinued before fluorouracil treatment.</p><p>&nbsp;</p><p>5-fluorouracil may cause genetic damage.</p><p>&nbsp;</p><p>If you are a man, you should avoid fathering a child during and for up to 6 months after the end of treatment with 5-Fluorouracil Ebewe. Because of the possibility of severe spermatogenesis impairment due to therapy with 5-Fluorouracil Ebewe, you should seek advice about sperm conservation prior to treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Title: Warndreick - Description: Symbol: Achtung" style='width:30.75pt;
 height:27pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.png"
  o:title="" cropright="-320f"/>
</v:shape><![endif]--><img width="41" height="36" alt="Title: Warndreick - Description: Symbol: Achtung" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.png" />&nbsp; Warning: This medicine can affect reactions and the ability to drive.</p><p>&nbsp;</p><p>5‑Fluorouracil may induce nausea, vomiting, side effects on nervous system and visual changes which could indirectly interfere ability to drive or use machines. Therefore, don&rsquo;t drive or use machines during the treatment with 5‑Fluorouracil.</p><p>&nbsp;</p><p><strong>5-Fluorouracil Ebewe contains sodium</strong></p><p>This medicine contains up to 9.31&nbsp;mg sodium (main component of salt) per ml, or 186.20&nbsp;mg per maximum daily dose. This is equivalent to 9.31% of the maximum daily dietary sodium intake in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The dose of medicine given to you depends on your illness, your body weight, if you have had recent surgery and how well your liver and kidneys are working. It also depends on the results of your blood tests. The dose should not exceed 1 g per day. Your first series of treatment may be given daily or at weekly intervals.</p><p>Further administrations may be given according to your response to treatment. You may also receive treatment in combination with radiotherapy.</p><p>The medicine can be diluted with glucose solution or saline solution before it is given to you. It will be given to you into a vein (intravenous application).</p><p>This can be administered either as a normal injection or as a slow injection via infusion.</p><p>&nbsp;</p><p><strong>If you are given more 5-Fluorouracil Ebewe than you should take</strong></p><p>As this medicine will be given to you when you are in hospital, it is unlikely that you will be given too much or too little. Talk to your doctor or pharmacist if you still have any concerns.</p><p>Blood tests are required during and after treatment with 5-Fluorouracil Ebewe to check your blood cell levels. If the level of white blood cells drops too low, treatment may have to be stopped.</p><p>Nausea, vomiting, diarrhoea, severe mucositis as well as gastrointestinal ulceration and bleeding may occur if you are given too much fluorouracil.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you notice any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reaction &ndash; you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), and you may feel you are going to faint;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe chest pain that appears during exertions;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloody or black stool, wounds or ulcers in the mouth, inflammation of the rectum or the anus, loss of appetite, watery diarrhoea, feeling unwell;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness, tingling sensation or shaking in the hands and feet;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid heartbeat and breathlessness, which may be signs of a heart failure;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused or feeling unsteady on your feet, coordination problems in arms and legs, thinking/speech difficulties, vision/memory problems;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath.</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10 people):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone marrow damage, i.e. too few red and/or white blood cells or platelets are formed (leukopenia, neutropenia, thrombocytopenia, anaemia);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cramping of the muscles encircling the respiratory tract (bronchospasm);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased uric acid levels in your blood (hyperuricaemia);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ECG changes (electric recording of your heart activity);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal disorders (partially life-threatening), such as inflammation of the oral mucosa, the throat, the oesophagus, and the rectum);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite (anorexia);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe (watery) diarrhoea, nausea, vomiting;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ldquo;hand-foot syndrome&rdquo; (toxic skin reaction; with somatosensory disorder, reddening, swelling, pain and scaling of the skin on palms and soles);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delayed wound healing;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nosebleeds;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exhaustion, general weakness, fatigue, loss of drive;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections.</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low count of certain white blood cells with fever (febrile neutropenia);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe (angina pectoris-like) chest pain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immunosuppression with increased risk of infection;</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nystagmus, headache, dizziness, symptoms of Parkinson&rsquo;s disease, pyramidal signs, euphoria, sleepiness;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased tear flow and narrowing of the tear duct;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, eye movement disturbance, double vision, decrease in visual acuity, sensitivity to light (photophobia), inflammation of the optic nerve/conjunctiva/eyelids, lower eyelid inversion (ectropion) due to scar formation, scarring of the tear ducts;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heartbeat, heart attack, insufficient supply to the heart muscle, inflammation of the heart muscle, impaired cardiac function (cardiac insufficiency), pathological increase in size of one or both heart chambers, failure of the pumping function of the heart (cardiogenic shock);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; formation of gastrointestinal ulcers and bleeding;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver cell damage, (non-calculous) gallbladder inflammation;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin inflammation, skin alterations (dry skin with cracking, redness, rash), nettle rash (urticaria), sensitivity to light, hyperpigmentation of the skin, stripy pigmentation changes along the veins, , changes in the nails, pain, thickening or inflammation of the nail bed, loss of nails;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sperm or egg production disorder.</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general allergic reactions, allergic shock;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vein inflammation;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; peripheral nerve disorder (in combination with radiotherapy);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood poisoning;</p><p>&nbsp;</p><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe decrease in granulocytes, a subgroup of the white blood cells, or severe decrease in blood cells of all systems (too few red and white blood cells and platelets);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired taste;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pathological changes to the white matter of the brain (leukoencephalopathy) with movement coordination disorders;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cerebellar damage;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech disorders (aphasia, dysarthria);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, loss of orientation;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsion or coma;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac arrest, sudden cardiac death;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver collapse.</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elevated thyroid levels;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperammonaemic encephalopathy (a functional disorder of the brain caused by increased ammonia values);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pericardium;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased brain, colon, and peripheral perfusion, Raynaud&rsquo;s syndrome (episodes of pale fingers and toes due to cramp-like narrowing of the blood vessels), blood vessels blocked due to clots (thromboembolism).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 25&deg;C. Do not refrigerate or freeze.</p><p>Store in the original packaging, to protect the content from light.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the carton after &ldquo;Use by&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>For single use only.</p><p>&nbsp;</p><p>Use only clear and colourless to slightly yellowish solutions.</p><p>&nbsp;</p><p>If precipitates have formed as a result of exposure to low temperatures, dissolve by careful heating to 60&deg;C and shaking. Allow to cool before use.</p><p>&nbsp;</p><p>The chemical and physical stability of the prepared solution for infusion has been demonstrated for over 28 days. From a microbiological point of view, however, the ready-to-use solution for infusion should be used immediately. If not used immediately, the storage conditions of the ready-to-use solution for infusion prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2&ndash;8&deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p><p>&nbsp;</p><p>Observe the disposal and handling regulations for cytostatic agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; The active substance is fluorouracil.</p><p>Each&nbsp;ml of concentration for solution for infusion contains 50&nbsp;mg of fluorouracil.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: Water for injections and sodium hydroxide (for pH adjustment)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medical product is a concentrate for solution for infusion.
Clear, colourless solution.
pH: 8.5–9.5

1 / 5 vials with 5 ml
1 / 5 vials with 10 ml
1 / 5 vials with 20 ml
1 vial with 100 ml

Type I amber glass vials with/without transparent PVC container (Onco-Safe).The vials are available in packs with one (1) and five (5) units, respectively. 

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorisation holder</strong><br />EBEWE Pharma Ges.m.b.H. Nfg. KG, 4866 Unterach, Austria</p><p><strong>Manufacturer</strong><br />Fareva Unterach GmbH, 4866 Unterach, Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار 5-فلورويوراسيل إيبيفيه على المادة الفعَّالة فلورويوراسيل. وهو دواء مضاد للسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار 5-فلورويوراسيل إيبيفيه لعلاج العديد من السرطانات الشائعة (الأورام الخبيثة)، وخاصة سرطانات الأمعاء الغليظة والمعدة والبنكرياس والثدي والرأس والعنق وعنق الرحم. يمكن استخدامه بمصاحبة مضادات السرطان الأخرى والعلاج الإشعاعي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم عقار 5-فلورويوراسيل إيبيفيه في الحالات الآتية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بحساسية تجاه فلورويوراسيل أو أي من المكونات الأخرى المدرجة في قسم: 6.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تغير تعداد الدم لديك بشكل ملحوظ أو إذا كنت تعاني من النزيف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور شديد بالكبد و/أو الكُلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى خطيرة (على سبيل المثال: الهربس النطاقي، الجدري المائي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الورم لديك غير خبيث (حميد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب الغشاء المخاطي بالفم (التهاب الفم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تقرحات في الفم أو الجهاز الهضمي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بالتهاب الأمعاء الدقيقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالضعف الشديد بسبب مرض طويل الأمد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدث تلف للنخاع العظمي لديك بسبب العلاجات الأخرى (بما في ذلك العلاج الإشعاعي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تتناول بريفودين كعلاج للجُدري المائي أو الهربس النطاقي، يسمى أيضًا باسم القوباء المنطقية.<br />قد يؤدي استخدام فلورويوراسيل بمصاحبة بريفودين إلى زيادة الآثار الجانبية لعقار 5-فلورويوراسيل إيبيفيه بشكل كبير. من الممكن لهذا التداخل الدَّوائي أن يسبب الوفاة. لذلك، يجب عليك عدم استخدام هذا الدواء مع العلاج الكيميائي بعقار فلورويوراسيل. يمكنك بدء العلاج الكيميائي بعقار 5-فلورويوراسيل بعد 4 أسابيع على الأقل من انتهاء علاج الهربس النطاقي باستخدام بريفودين. إذا كنت تتلقى علاجًا من عدوى الهربس النطاقي أو عولجت مؤخرًا، فيرجى إبلاغ طبيبك بالأدوية التي تناولتها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو مرضعًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرف أنك ليس لديك أي نشاط لإنزيم نازعة هيدروجين ثنائي البيريميدين (DPD).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتسبب الجرعات المعتادة من عقار 5-فلورويوراسيل في حدوث آثار جانبية مكثفة في المرضى الذين يعانون من نقص إنزيم نازعة هيدروجين ثنائي البيريميدين. في حالة حدوث آثار جانبية شديدة، من الممكن أن يوصى بفحص نشاط إنزيم نازعة هيدروجين ثنائي البيريميدين. يجب عدم علاج المرضى الذين يعانون من نقص نازعة هيدروجين ثنائي البيريميدين بعقار 5- فلورويوراسيل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التطعيم باللقاحات الحية (على سبيل المثال: الحصبة أو التهاب الغدة النكافية أو الحصبة الألمانية) أثناء العلاج بعقار 5- فلورويوراسيل. يجب تجنب كافة أشكال الملامسة مع لقاحات شلل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يجب أَلَّا يُوصف عقار 5-فلورويوراسيل إيبيفيه إِلَّا من قِبَل أطباءٍ ذوي خبرة كافية في علاج الأمراض ذات الصلة بفلورويوراسيل.</p><p dir="RTL">يُرجى استشارة طبيبك قبل استخدام عقار 5-فلورويوراسيل إيبيفيه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبح عدد الخلايا في دمك منخفضًا جدًّا (ستخضع لاختبارات دم لتحديد ذلك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكُلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتَ تُعاني من مشاكل في الكبد، بما في ذلك &quot;اليرقان&quot; (تغير لون الجلد إلى اللون الأصفر).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في القلب. أخبر طبيبك إذا أُصبت بألم بالصدر أثناء العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرف أنك تعاني من نقص جزئي في نشاط إنزيم نازعة هيدروجين ثنائي البيريميدين (DPD)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لعلاج إشعاعي على منطقة الحوض بجرعة عالية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت الآثار الجانبية التالية: التهاب الأغشية المخاطية داخل الفم أو الأغشية المخاطية الأخرى، إسهال، نزيف من الجهاز الهضمي أو نزيف في أماكن أخرى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>نقص إنزيم نازعة هيدروجين ثنائي البيريميدين</u><u>: </u></p><p dir="RTL">نقص إنزيم نازعة هيدروجين ثنائي البيريميدين عبارة عن حالة نادرة توجد عند الولادة ولا ترتبط عادةً بالمشكلات الصحية ما لم تتلقى أدوية معينة. إذا كنت تعاني من نقص إنزيم نازعة هيدروجين ثنائي البيريميدين غير المعروف وتناولت عقار 5- فلورويوراسيل، فأنت معرض لزيادة خطر الإصابة بظهور أشكال حادة ومبكرة من الآثار الجانبية الشديدة المدرجة تحت القسم 4، &quot;الآثار الجانبية المحتملة&quot;. إذا ساورتك أي مخاوف بشأن هذه الآثار الجانبية، أو إذا لاحظت أي آثار جانبية إضافية غير مدرجة في هذه النشرة (انظر القسم 4، &quot;الآثار الجانبية المحتملة&quot;)، فتحدث إلى طبيبك فورًا.</p><p dir="RTL">يُرجى إبلاغ طبيبك فورًا إذا لاحظت أيًّا مما يلي من العلامات أو الأعراض: ظهور ارتباك/التباس، توهان أو تغيرات أخرى بالحالة النفسية، اضطرابات بالاتزان أو الاتساق، اضطرابات بصرية. من الممكن أن تكون هذه علامات على الإصابة باعْتِلَال دِّماغِي (حالات باثولوجية (مرضية بالمخ)) التي قد تؤدي إلى غيبوبة والوفاة في حالة عدم علاجها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون</u></p><p dir="RTL">الخبرات غير كافية بشأن فعالية استخدام عقار 5- فلورويوراسيل للأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وعقار 5-فلورويوراسيل إيبيفيه</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول/تستخدم أو تناولت/استخدمت مؤخرًا أو قد تتناول/تستخدم أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى تذكر إبلاغ طبيبك حول العلاج بالفلورويوراسيل، إذا وصف لك الطبيب أدوية أخرى أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عليك عدم تناول بريفودين </strong><strong>(</strong><strong>دواء مضاد للفيروسات يستخدم لعلاج الهربس النطاقي أو الجُدري المائي</strong><strong>) </strong><strong>في&nbsp; وقت العلاج نفسه بعقار </strong><strong>5-</strong><strong>فلورويوراسيل </strong><strong>(</strong><strong>بما في ذلك خلال أي فترات راحة عندما لا تتناول أي أقراص من عقار </strong><strong>5-</strong><strong>فلورويوراسيل</strong><strong>).</strong></p><p dir="RTL"><strong>إذا كنت قد تناولت بريفودين، فيجب عليك الانتظار لمدة ٤ أسابيع على الأقل بعد إيقاف بريفودين قبل بدء تناوُل عقار </strong><strong>5- </strong><strong>فلورويوراسيل</strong><strong>. </strong><strong>انظر أيضًا قسم </strong><strong>&quot;</strong><strong>لا تستخدم عقار </strong><strong>5- </strong><strong>فلورويوراسيل إيبيفيه في الحالات الآتية</strong><strong>:&quot;.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يُعد إبلاغ طبيبك بتناوُلك/ استخدامك لأيٍّ من العقاقير التَّالية هامًّا بشكل خاص:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات، فينوريلبين، سيكلوفوسفاميد، ميتوميسين سي، تاموكسيفين (أدوية مضادة للسرطان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميترونيدازول (مضاد حيوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوكوفورين الكالسيوم (يُسمى أيضًا فولينات الكالسيوم -للحد من الآثار الضَّارة للأدوية المضادة للسرطان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألوبيورينول (يُستخدم في علاج النَّقْرِس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيميتيدين (يُستخدم لعلاج قرح المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين (يُستَخدَم لعلاج جلطات الدَّم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سِيسْبلاتين (دواء مضاد للسرطان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (يستخدم للتحكم في مرض الصرع/نوبات التشنج واضطرابات النظم القلبي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللقاحات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليفاميسول (دواء يستخدم لعلاج عدوى الديدان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلورديازبوكسيد (مهدئ)، دايسلفيرام (في حالة إدمان الكحوليات)، جريزوفولفين (لعلاج العدوى الفطرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمينوفينازون (مسكن)، فينيل بوتازون (مضاد للروماتيزم)، وسَلفوناميد (مضاد حيوي)</p><p dir="RTL">تُؤثر الأدوية المذكورة أعلاه على مفعول الفلورويوراسيل.</p><p dir="RTL">يجب ألا يُخلَط فولينات الكالسيوم مع عقار 5- فلورويوراسيل في نفس الحقنة بالوريد أو التسريب في الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بإمكان فلورويوراسيل أن يزيد من التأثير السام الناجم عن العلاج الإشعاعي على الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبكِ قبل تناوُل هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم إعطاء فلورويوراسيل أثناء فترة الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بصفتك امرأة في سن الإنجاب، يجب عليكِ استخدام وسيلة فعالة لمنع الحمل أثناء استخدام هذا الدواء ولمدة 6 أشهر على الأقل بعد ذلك. إذا أصبحتِ حاملًا أثناء علاجكِ على الرغم من ذلك، يجب عليكِ إبلاغُ طبيبكِ والحصول على الاستشارة الوراثية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأنه من غير المعلوم ما إذا كان فلورويوراسيل يفرز في حليب ثدي الأمهات أم لا، فإنه يجب على الأمهات المرضعات التوقف عن إرضاع أطفالهن قبل العلاج بفلورويوراسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب عقار 5-فلورويوراسيل ضررًا جينيًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي على الرجال عدم الإنجاب أثناء العلاج بعقار 5- فلورويوراسيل إيبيفيه وحتى ما يصل إلى ٦ أشهر بعد انتهاء العلاج به. نظرًا لاحتمالية حدوث ضعف شديد في تكوين الحيوانات المنوية نتيجة للعلاج بعقار 5- فلورويوراسيل إيبيفيه، يجب عليك طلب المشورة بشأن حفظ الحيوانات المنوية قبل العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Title: Warndreick - Description: Symbol: Achtung" style='width:30.75pt;
 height:27pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQCxgme2CgEAABMCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRwU7DMAyG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">
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.png"
  o:title="" cropright="-320f"/>
</v:shape><![endif]--><img width="41" height="36" alt="Title: Warndreick - Description: Symbol: Achtung" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.png" />&nbsp; تحذير: بإمكان هذا الدَّواء أن يُؤثر على ردود الفعل والقدرة على القيادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب عقار 5- فلورويوراسيل الغثيان والقيء والآثار الجانبية على الجهاز العصبي والتغيرات البصرية التي يمكن أن تتداخل بشكل غير مباشر مع القدرة على القيادة أو استخدام الآلات. لذلك، لا تمارس القيادة أو تستخدم الآلات أثناء العلاج بعقار 5- فلورويوراسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار 5-فلورويوراسيل إيبيفيه على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدَّواء على ٩.٣۱ مجم صوديوم (المكون الرئيسي لملح المائدة/ الطعام) لكل مللي لتر أو ۱٨٦.٢٠ مجم لكل جرعة يومية قصوى. هذا يعادل 9.31٪ من الحد الأقصى الذي ينبغي تناوله من الصوديوم يوميًّا في الغذاء للبالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تعتمد الجرعة التي يتم إعطاؤك إياها من العقار على مرضك، ووزن الجسم، وإذا ما كنتَ قد خضعت لجراحة حديثة أم لا، ومدى كفاءة وظائف الكبد والكُلى لديك. تعتمد الجرعة أيضًا على نتائج اختبارات الدَّم الخاصة بك. يجب أَلَّا تتجاوز الجرعة 1 جرام يوميًّا. قد يتم إعطاء الدورة الأولى الخاصة بك من العلاج يوميًّا أو على فترات أسبوعية.</p><p dir="RTL">قد يتم إعطاء مرات إضافية وفقًا لاستجابتك للعلاج. قد تتلقى أيضًا العلاج بمصاحبة العلاج الإشعاعي.</p><p dir="RTL">من الممكن تخفيف الدواء باستخدام محلول الجلوكوز أو محلول ملحي قبل إعطائه لك. وسيتم إعطاؤه لك في الوريد.</p><p dir="RTL">من الممكن إعطاء ذلك إما في هيئة حقن عادي أو في هيئة حقن بطيء عن طريق التسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تلقيت كمية أكبر مما يجب من عقار 5-فلورويوراسيل إيبيفيه</strong></p><p dir="RTL">نظرًا إلى أنَّ هذا الدَّواء سيتم إعطاؤه لك أثناء وجودك في المستشفى، فمن غير المُحتَمل أن تتلقى كمية أكثر أو أقل مما يجب. إذا ما زلت قلقًا، فتحدَّث إلى الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">يجب إجراء اختبار الدَّم أثناء العلاج بعقار 5-فلورويوراسيل إيبيفيه وبعده للتَّحقق من تعداد خلايا الدَّم لديك. إذا انخفض مستوى خلايا الدم البيضاء للغاية، فقد يلزم إيقاف العلاج.</p><p dir="RTL">قد يحدث غثيان، قيء، إِسْهال، التهاب شديد بالأغشية المخاطية وكذلك قُرَح ونزيف في الجهاز الهضمي إذا تم إعطاؤك كمية كبيرة جدًّا من فلورويوراسيل.</p><p dir="RTL">اسأل طبيبك في حالة وجود أية أسئلة إضافية متعلقة باستخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، يمكن أن يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">يُرجى إبلاغ طبيبك فورًا إذا لاحظت أيًّا مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة - قد تصاب فجأة بطفح جلدي مصحوب بحكة (شرى أو أرتكاريا)، تورم اليدين، القدمين، الكاحلين، الوجه، الشفتين، الفم أو الحلق (مما قد يسبب صعوبة في البلع أو التنفس)، وقد تشعر بأنك ستصاب بالإغماء؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد بالصدر والذي يظهر أثناء حالات بذل مجهود؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبرز براز أسود أو به دم، جروح أو قرح بالفم، التهاب المستقيم أو فتحة الشرج، فقدان الشهية، إسهال مائي، الشعور بالتوعك؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بتنميل أو وخز أو ارتعاش باليدين والقدمين؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب وعُسْر التَّنَفُّس، الذي قد يكون علامات على الإصابة بفشل القلب؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالارتباك أو عدم الثبات على قدميك، مشاكل التناسق في الذراعين والساقين، صعوبات التفكير/الكلام، مشاكل بالرؤية/الذاكرة؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق بالتَّنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جدًّا (قد تُؤثر في أكثر من شخص واحد من كل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف النخاع العظمي، أي الانخفاض الشديد في تكوين خلايا الدَّم الحمراء و/أو خلايا الدَّم البيضاء أو الصفائح الدموية (قلَّةُ كرَيَّاتِ الدم البيْضاء، قلة خلايا العَدِلات، نقص الصَّفائح الدَّموية، فقر الدم)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات بالعضلات المحيطة بالجهاز التَّنفسي (التشنجات القصبية)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات حمض اليوريك في الدَّم (فرط حمض اليوريك بالدَّم)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في رسم القلب الكهربائي (تسجيل إلكتروني للنَّشاط القلبي لديك)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الجهاز الهضمي (تهدد الحياة بشكل جزئي)، مثل التهاب الأغشية المخاطية بالفم والحلق والمريء والمستقيم)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال (مائي) شديد، غثيان، قيء؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;متلازمة اليد والقدم&quot;(تفاعل سام بالجلد؛ مع اضطراب حسي، احمرار، وتورم، وألم وتقشر الجلد على راحتي اليدين وباطني القدمين)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التئام الجروح ببطء؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنهاك أو ضعف عام أو إرهاق أو فقدان الرغبة؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة عدد خلايا معينة من خلايا الدَّم البيضاء المصحوب بالحمى (الحمى النَّاجمة عن قلة خلايا العَدِلات &quot;قلة العدلات الحُمّوي&quot;)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد بالصدر (حالة شبيهة بالذبحة الصدرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبت المناعة مع زيادة خطر الإصابة بالعدوى؛</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل ١٠٠شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رَأْرَأَة، صداع، دوخة، أعراض مرض باركنسون، أعراض السبيل الهرمي، نشوة، نعاس؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفراز الدموع وتضيق القناة الدمعية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية، اضطرابات حركة العين، ازدواج الرؤية، انخفاض حدة الإبصار، حساسية تجاه الضوء (رهاب الضوء)، التهاب عصب البصر/ الملتحمة/الجفون، انقلاب الجفن السفلي للخارج (شَتَر خارِجِيّ) بسبب تكون الندبات، ظهور ندبات بالقنوات الدمعية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب، نوبة قلبية، عدم كفاية إمداد عضلة القلب، التهاب عضلة القلب، قصور وظائف القلب (قصور القلب)، زيادة باثولوجية في حجم غرفة واحدة أو كلتا غرفتي القلب، فشل في وظيفة ضخ الدم من القلب (صدمة قلبية)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوُن قرح ونزيف بالمعدة والأمعاء؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف خلايا الكبد، التهاب المرارة (بدون حصى)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد، تغييرات بالجلد (جفاف الجلد وتشققه، احمرار، طفح جلدي)، طفح القراص (أرتكاريا)، حساسية تجاه الضوء، فَرْط تصبغ الجلد، تغييرات مخططة في التصبغ على طول الأوردة، تغييرات في الأظافر، ألم أو التهاب أو زيادة سماكة فِراش الظُّفُر، فقدان الأظافر؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في إنتاج الحيوانات المنوية أو البويضات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية عامة، صدمة الحساسية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الأعصاب الطرفية (بمصاحبة العلاج الإشعاعي)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم الدم؛</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة جدًّا (قد تُؤثر على ما يصل إلى شخص واحد من كل 10000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في الخلايا المحببة، مجموعة فرعية من خلايا الدَّم البيضاء، أو انخفاض شديد في عدد خلايا الدم في جميع الأجهزة (انخفاض شديد في عدد خلايا الدم الحمراء وخلايا الدم البيضاء والصفائح الدموية)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف حاسة التَّذوق؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات باثولوجية بالمادة البيضاء بالمخ (اعْتِلالُ بَيضاءِ الدِّماغِ) مع اضطرابات اتساق الحركة؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف مُخَيْخِيّ؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الكلام (فقدان القدرة على الكلام، عسر التلفظ)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك/التباس، فقدان التَوَجُّه؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج أو غَيبوبَة؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة قلبية، الوفاة القلبية المفاجئة؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات هرمون الغدة الدرقية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعْتِلَال دِماغِيّ ناجم عن فَرْط أَمُونْيا الدَّم (خلل في وظائف الدماغ ناجم عن زيادة مستويات الأمونيا)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب التأمور؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في تروية المخ والقولون والتروية الطرفية، متلازمة رينود (نوبات شحوب أصابع اليدين والقدمين بسبب تضيق الأوعية الدموية الشبيهة بالتقلصات)، انسداد الأوعية الدموية الناجم عن الجلطات (الانصمام الخثاري).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ في درجة حرارة أقل من 25 درجة مئوية. لا تقم بتبريده أو تجميده.</p><p dir="RTL">يُحفظ في العبوة الأصلية، لحماية المحتويات من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة بعد كلمة &quot;Use by&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للاستخدام مرة واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل المحاليل إلا إذا كانت صافية وعديمة اللون التي تميل إلى الأصفر قليلًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تكونت ترسبات نتيجة التعرض لدرجات حرارة منخفضة، تتم إذابة تلك الترسبات عن طريق التسخين بعناية إلى درجة حرارة تصل إلى ٦٠ درجة مئوية ورجها. اتركها لتبرد قبل الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتضح وجود ثبات كيميائي وفيزيائي لمحلول التسريب المعد للاستخدام لمدة تزيد عن ٢٨ يومًا. مع ذلك، فمن وجهة النَّظر الميكروبيولوجية، يجب استخدام هذا المحلول المُعَد للتسريب فورًا. إذا لم يُستخدم على الفور، تكون ظروف تَخزين محلول التسريب قبل الاستخدام مسؤولية المستخدم وعادةً لن تكون أطول من 24 ساعة عند درجة حرارة 2 - 8 درجات مئوية، إِلَّا إذا كان قد تم تخفيف المستحضر في ظروف تعقيم مضبطة وتم التَّحقق منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى مراعاة أنظمة التخلص والمناولة بالنسبة للأدوية المثبطة لنمو الخلايا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي فلورويوراسيل.</p><p dir="RTL">يحتوي كل مللي لتر من المركز لمحلول التسريب على 50 مجم من فلورويوراسيل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: ماء لأغراض الحقن وهيدروكسيد الصوديوم (لضبط درجة الحموضة)</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هذا المنتج الدَّوائي هو مادة مُركَّزة؛ لإعداد محلول للتَّسريب.</p><p dir="RTL">محلول صافٍ، بدون لون.</p><p dir="RTL">درجة الحموضة: 8.5 &ndash; 9.5</p><p dir="RTL">&nbsp;</p><p dir="RTL">زجاجة واحدة، أو 5 زجاجات تحتوي على 5 مللي لترات.</p><p dir="RTL">زجاجة واحدة، أو 5 زجاجات تحتوي على 10 مللي لترات.</p><p dir="RTL">زجاجة واحدة، أو 5 زجاجات تحتوي على 20 مللي لترًا.</p><p dir="RTL">زجاجة واحدة تحتوي على 100 مللي لتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عبوات زجاجية كهرمانية من النوع I مع/بدون حاوية شفافة من بولي فينيل الكلوريد (Onco-Safe). تتوافر العبوات الزجاجية في عبوات بها وحدة واحدة (1) وخمس (5) وحدات، على التوالي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسَّويق</strong><br />شركة إيبيفيه فارما المحدودة Nfg. شراكة محدودة 4866 أونتراخ، النمسا</p><p dir="RTL"><strong>جهة التصَّنيع</strong><br />شركة فاريفا أونتراخ المحدودة<br />4866 أونتراخ، النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5-Fluorouracil Ebewe 50 mg/ml – Concentration for solution for infusion


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of concentrate for solution for infusion contains 50 mg of fluorouracil.

Excipient with known effect: 
Each ml of concentrate for solution for infusion contains 14.7 mg of sodium hydroxide

For a full list of excipients see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
Clear, colourless solution.
pH: 8.5–9.5



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adjuvant or palliative treatment of</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced colorectal cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced gastric cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced pancreatic cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced and/or metastatic breast cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced tumours of the head and neck area</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced cervical cancer</p><p>&nbsp;</p><p>5-Fluorouracil Ebewe 50 mg/ml &ndash; Concentration for solution for infusion is used in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with 5-fluorouracil should be administered only by doctors with experience in tumour therapy. In the initial phase, hospitalisation of the patient should be considered.</p><p>&nbsp;</p><p>5-fluorouracil is used in mono-chemotherapy and as a component of poly-chemotherapy. Since the method of application and dose recommendation for 5-fluorouracil vary widely, only general reference values can be given.</p><p>&nbsp;</p><p>The exact dosage should be taken from treatment protocols that have proved effective in the particular disease.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><strong><u>Posology</u></strong></p><p><strong>Initial therapy in daily use:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as IV infusion</p><p>15&nbsp;mg/kg or 600&nbsp;mg/m&sup2; over 4 hours daily &ndash; until the onset of undesirable effects.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as IV injection</p><p>slow IV administration of 12&nbsp;mg/kg or 480&nbsp;mg/m&sup2; (2 to 3 minutes) on days 1, 2 and 3&nbsp;;</p><p>if no signs of toxicity are evident &ndash; administration of 6&nbsp;mg/kg or 240&nbsp;mg/m&sup2; on day 5, 7 and 9.&nbsp;.</p><p>&nbsp;</p><p><strong>Initial therapy in weekly use:</strong></p><p>Slow IV administration of 15&nbsp;mg/kg or 600&nbsp;mg/m&sup2; once weekly.</p><p>&nbsp;</p><p><strong>Maintenance therapy:</strong></p><p>Once remission has been achieved or rather after the abatement of undesirable effects and further increase in leukocytes up to 3,000 to 4,000/&micro;l, in thrombocytes up to 80,000 to 100,000/&micro;l: 5&ndash;10&nbsp;mg/kg or 200&ndash;400&nbsp;mg/m&sup2; IV once weekly.</p><p>&nbsp;</p><p>The <u>maximum daily dose </u>of 1&nbsp;g must not be exceeded.</p><p>&nbsp;</p><p>All dosage information applies to normal weight, i.e. in obesity, ascites or oedema, dosages must be standardised accordingly.</p><p>&nbsp;</p><p>The <u>duration of treatment</u><u> </u>depends on the nature and progress of the disease and is determined by an experienced specialist or in accordance with the treatment protocol.</p><p>&nbsp;</p><p>When 5‑Fluorouracil is combined with other cytostatic agents with a similar safety profile or with radiotherapy, the dose must be reduced accordingly. It can be administered in the form of a 24-hour continuous drip infusion.</p><p>&nbsp;</p><p><strong><u>Method of administration</u></strong></p><p>For intravenous use.</p><p>5-fluorouracil must be applied strictly into the vein. It can be injected or infused after dilution with 0.9% NaCl solution or 5% glucose.</p><p>&nbsp;</p><p>Extravascular application must be avoided.</p><p>&nbsp;</p><p><u>Special dosage instructions:</u></p><p>The recommended doses should be reduced by one third to one half in patients with poor nutritional condition, after a major surgical intervention, in myelosuppression (leucocytes &lt;&nbsp;4,000/&micro;l, thrombocytes &lt;&nbsp;100,000/&micro;l) and severe hepatic and renal impairment.</p><p>&nbsp;</p><p><u>Renal or hepatic dysfunction:</u></p><p>In patients with renal or hepatic dysfunction, caution should be exercised and the dose reduced if necessary.&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><u>Elderly persons (aged 65 or more): </u></p><p>No initial dose adjustment is required. Careful monitoring of elderly patients is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5-fluorouracil is contraindicated in: 

-	hypersensitivity to the active substance or any of the excipients listed in section 6.1
-	significant changes in the blood count 
-	bone marrow depression
-	haemorrhagia 
-	severe hepatic and/or renal impairment
-	acute, severe infections (e.g. herpes zoster, varicella)
-	stomatitis 
-	oral and gastrointestinal tract ulcerations 
-	pseudomembranous enteritis
-	patients in poor general condition
-	during pregnancy and breast-feeding (see section 4.6)
-	patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity (see section 4.4)
-	recent or concomitant treatment with brivudine (see sections 4.4 and 4.5 for interactions)

Brivudine is a potent inhibitor of the enzyme dihydropyrimidine dehydrogenase (DPD), which breaks down 5-fluorouracil.

In patients who have dihydropyrimidine dehydrogenase deficiency, normal 5-flourouracil doses can provoke intensified undesirable effects. If serious undesirable effects occur, a DPD activity screening may be indicated. Patients with dihydropyrimidine dehydrogenase deficiency must not be treated with 5-flourouracil.

Vaccination with a live vaccine must not be administered concomitantly with a 5-fluorouracil therapy. All contact with poliomyelitis vaccines should be avoided.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Precautions for handling and use of 5-fluorouracil</u></p><p>Due to the possible mutagenic and carcinogenic effects, enhanced safety precautions for hospital staff and physicians apply. While handling 5-fluorouracil, any contact with skin and mucosa should be avoided. Failing this, immediately wash with soap and water. In the event of eye contamination, rinse immediately with water and seek medical advice. All provisions must be made to allow for completely aseptic work. The use of a workspace with laminar flow is recommended. Protective clothing must be worn while handling 5-fluorouracil.</p><p>&nbsp;</p><p>Pregnant staff must not work with 5-fluorouracil.</p><p>&nbsp;</p><p><u>Cardiotoxicity</u></p><p>Treatment with fluoropyrimidines has been associated with cardiotoxicity, including myocardial infarction, angina pectoris, arrhythmias, myocarditis, cardiogenic shock, sudden death, and ECG changes (including QT interval prolongation in very rare cases). These undesirable effects appear more frequently in patients receiving a continuous infusion with 5-flourouracil than in patients receiving a bolus injection. A history of coronary heart disease may be a risk factor for cardiac undesirable effects. Caution is therefore indicated when treating patients who experienced chest pain during courses of treatment, or patients with a history of heart disease. Cardiac function should be regularly monitored during treatment with fluorouracil. In case of severe cardiotoxicity, the treatment should be discontinued.</p><p>&nbsp;</p><p><u>Encephalopathy</u></p><p>Cases of encephalopathies (including hyperammonaemic encephalopathy, leukoencephalopathy) associated with 5-fluorouracil treatment have been reported from post-marketing sources. Signs or symptoms of encephalopathy are altered mental status, confusion, disorientation, coma or ataxia. If a patient develops any of these symptoms, withhold treatment and test serum ammonia levels immediately. In case of elevated serum ammonia levels initiate ammonia-lowering therapy.</p><p>&nbsp;</p><p>Caution is necessary when administering fluorouracil to patients with renal and/or hepatic impairment. Patients with impaired renal and/or hepatic function may have an increased risk of hyperammonaemia and hyperammonaemic encephalopathy.</p><p>&nbsp;</p><p><u>Dihydropyrimidine dehydrogenase (DPD) deficiency</u></p><p>The enzyme dihydropyrimidine dehydrogenase (DPD) plays an important role in breaking down 5-fluorouracil. Nucleoside analogues, e.g. brivudine and sorivudine, may cause increased plasma concentrations of 5‑fluorouracil and other fluoropyrimidines and thus to an associated increase in toxicity. Therefore, an interval of at least 4 weeks between administration of 5-fluorouracil and brivudine, sorivudine, or analogues should be maintained.</p><p>&nbsp;</p><p>Brivudine must not be administered concomitantly with 5-fluorouracil. Fatalities have been reported following this drug interaction. There must be at least a 4-week waiting period between end of treatment with brivudine and start of 5-fluorouracil therapy. Treatment with brivudine can be started 24 hours after the last dose of 5-fluorouracil (see sections 4.3 and 4.5). If applicable, determination of DPD enzyme activity is indicated prior to the treatment with 5-fluorouracil.</p><p>&nbsp;</p><p>In case of an inadvertent administration of brivudine to patients receiving 5-fluorouracil, effective measures should be taken to reduce the 5-fluorouracil toxicity. Immediate hospitalisation is recommended. All measures should be initiated to prevent systemic infections and dehydration.</p><p>&nbsp;</p><p>Rare, unexpected and severe toxicity (e.g. stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-FU has been attributed to limited DPD activity. Patients with low or absent activity of DPD, an enzyme involved in fluorouracil elimination, are at increased risk of severe, life-threatening, or fatal adverse reactions caused by fluorouracil. Although DPD deficiency cannot be precisely defined, it is known that patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus (e.g. DPYD*2A, c.1679T&gt;G, c.2846A&gt;T and c.1236G&gt;A/HapB3), which can cause complete or near complete absence of DPD enzymatic activity (as determined from laboratory assays), have the highest risk of life-threatening or fatal adverse reaction and should not be treated with 5-fluorouracil (see section 4.3). No dosage has been proven safe for patients with complete absence of DPD activity.</p><p>Patients with certain heterozygous DPYD variants (including DPYD*2A, c.1679T&gt;G, c.2846A&gt;T and c.1236G&gt;A/HapB3 variants) have been shown to have increased risk of severe toxicity when treated with fluoropyrimidines.</p><p>&nbsp;</p><p>The frequency of the heterozygous DPYD*2A genotype in the DPYD gene in Caucasian patients is around 1%, 1.1% for c.2846A&gt;T, 2.6&ndash;6.3% for c.1236G&gt;A/HapB3 variants and 0.07 to 0.1% for c.1679T&gt;G. Genotyping for this allele is recommended to identify patients at increased risk of severe toxicity. Data on the frequency of these DPYD variants in populations other than Caucasian is limited. It cannot be ruled out that other rare variants may also be associated with an increased risk of severe toxicity.</p><p>&nbsp;</p><p>For patients with partial DPD deficiency (such as those with heterozygous mutations in the DPYD gene) and where the benefits of 5-flourouracil are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these individuals must be treated with extreme caution and frequent monitoring with dose adjustment according to toxicity. In such patients a reduction of the starting dose should be considered to prevent severe toxicity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by specific test. It has been reported that the DPYD*2A, c.1679T&gt;G variants lead to a greater reduction in enzymatic activity compared to other variants with a higher risk of undesirable effects. The consequences of a reduced dose on the efficacy are currently uncertain. Therefore, in the absence of serious toxicity the dose could be increased while carefully monitoring of the patient. The patients who are tested negative for the above-mentioned allele may still have a risk of severe undesirable effects.</p><p>&nbsp;</p><p>In patients with unrecognised DPD deficiency treated with 5-fluoruracil as well as in those patients who test negative for specific DPYD variations, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9). In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately. Permanent discontinuation should be considered based on clinical assessment of the onset, duration and severity of the observed toxicities.</p><p>&nbsp;</p><p>Due to the possibility of anaphylactic reaction, the usual anti-shock measures should be provided prior to the use of 5-fluorouracil.</p><p>&nbsp;</p><p>Patients taking phenytoin concomitantly with 5-fluorouracil should undergo regular testing because of the possibility of an elevated phenytoin plasma level.</p><p>&nbsp;</p><p>Damage to the intestinal wall requires symptomatic treatment depending on severity, for example fluid substitution. Mild diarrhoea can be treated with antidiarrhoeal agents. However, these are not sufficient in moderate to severe diarrhoea.</p><p>&nbsp;</p><p>Prior to and during treatment with 5-fluorouracil, the following investigations are recommended:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; daily inspection of the oral cavity and pharynx for changes in the mucosa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood count including differential blood count and thrombocytes prior to each administration of 5-fluorouracil, and every 2‒3 days at the beginning of treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; retention values at regular intervals</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver parameters at regular intervals</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; determination of uric acid levels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stool tests for occult blood</p><p>&nbsp;</p><p>Patients should be informed that stomatitis/mucositis, diarrhoea and bleeding (especially from the gastrointestinal tract) may occur. They should be instructed to consult their doctor at the first signs. Immediate discontinuation of treatment is required with the following symptoms: gastrointestinal reactions (stomatitis, mucositis, severe diarrhoea, severe vomiting, ulcers, bleeding), leukocytes &lt;&nbsp;3,000/&micro;l, thrombocytes &lt;&nbsp;80,000/&micro;l, central undesirable effects (including ataxia and tremor) and cardiac undesirable effects.</p><p>&nbsp;</p><p>The treatment can be continued only after abatement of the undesirable effects and if the patient&rsquo;s general condition allows. In severe gastrointestinal, cardiac or neurological toxicity symptoms, resuming therapy is generally not recommended.</p><p>&nbsp;</p><p>In concomitant administration of 5-fluorouracil and oral anticoagulants, the Quick value must be closely monitored.</p><p>&nbsp;</p><p>Special caution is advised in high-risk patients who have had high-dose pelvic radiation, after therapy with alkylating substances, in extensive bone metastases and extensive hepatic metastases (reduced elimination!) and in cachectic patients.<em> </em></p><p>&nbsp;</p><p>In combination with methotrexate, methotrexate must be applied up to 24 hours prior to 5-fluorouracil (not vice-versa!) to achieve optimum effect.</p><p>&nbsp;</p><p>5-fluorouracil can be mutagenic. Male patients treated with 5-fluorouracil are therefore advised not to father a child during and up to 6 months following treatment, and to seek advice on sperm preservation before the start of therapy due to the possibility of severe spermatogenesis impairment. Female patients must not get pregnant during therapy with 5-fluorouracil and must use effective contraceptive measures.</p><p>When planning a child after treatment discontinuation, genetic counselling is recommended.</p><p>&nbsp;</p><p><u>Paediatric population:</u></p><p>There is insufficient experience of the use of 5-fluorouracil in children and adolescents.</p><p>&nbsp;</p><p><u>5-Fluorouracil Ebewe contains sodium</u></p><p>This medicine contains up to 9.31&nbsp;mg sodium per ml, or 186.20&nbsp;mg per maximum daily dose. This is equivalent to 9.31% of the WHO-recommended daily dietary intake of sodium, which is 2&nbsp;g.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Please note that the following information can also apply to recently administered medicinal products.</p><p>&nbsp;</p><p><u>Brivudine </u></p><p>A clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described. This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal. Therefore, brivudine must not be administered concomitantly with 5-fluorouracil (see section 4.3 and 4.4). There must be at least a 4-week waiting period between end of treatment with brivudine and start of 5-fluorouracil therapy. Treatment with brivudine can be started 24 hours after the last dose of 5-fluorouracil. If applicable, determination of DPD enzyme activity is indicated prior to the treatment with 5-fluorouracil.</p><p>&nbsp;</p><p>All therapeutic measures that worsen the patient&rsquo;s physical condition or that have myeloid effects (e.g. other cytostatic agents) can increase 5-fluorouracil toxicity.</p><p>&nbsp;</p><p>Fluorouracil can enhance skin toxicity of radiotherapy.</p><p>&nbsp;</p><p>Calcium folinate can enhance the effect of 5-fluorouracil. The clinical consequence of this interaction can be severe, sometimes fatal diarrhoea. An increased number of such fatalities was reported particularly in connection with an administration schedule of an IV bolus injection of 600 mg of 5-fluorouracil per m<sup>2</sup> body surface once per week combined with calcium folinate.</p><p>&nbsp;</p><p>In concomitant administration of phenytoin and 5-fluorouracil, an increase of phenytoin plasma concentration has been reported, resulting in symptoms of phenytoin intoxication.</p><p>&nbsp;</p><p>Cimetidine, metronidazole, allopurinol, and interferons can increase the plasma levels of 5-flourouracil. This can increase the toxic effects of 5-fluorouracil.</p><p>&nbsp;</p><p>In female patients receiving thiazide-type diuretics in addition to cyclophosphamide, methotrexate and 5-fluorouracil, the decrease in the number of granulocytes was more pronounced when compared to an equal number of cytostatic cycles without thiazide.</p><p>&nbsp;</p><p>In concomitant administration of 5-fluorouracil and warfarin, prothrombin time may be prolonged, so this should be closely monitored. There were isolated cases of patients treated with warfarin and adjuvant 5-fluorouracil alone or in combination with levamisole, in whom a decrease in the Quick value was observed.</p><p>&nbsp;</p><p>Hepatotoxicity (increase in alkaline phosphatases, transaminases or bilirubin) has been observed commonly in concomitant treatment with 5-fluorouracil <u>and</u> levamisole.</p><p>&nbsp;</p><p>In patients with breast cancer, combination therapy with cyclophosphamide, methotrexate, 5-fluorouracil and tamoxifen has been reported to increase the risk of thromboembolic events.</p><p>&nbsp;</p><p>Severe, potentially fatal mucositis can occur in concomitant administration of vinorelbine and 5-fluorouracil/folinic acid.</p><p>&nbsp;</p><p>Assay techniques for bilirubin and 5-hydroxyindolacetic acid can yield increased or false positive values.</p><p>&nbsp;</p><p>Aminophenazones, phenylbutazones and sulphonamides should not be given prior to and during treatment.</p><p>&nbsp;</p><p>Chlordiazepoxide, disulfiram, griseofulvin and isoniazid can enhance the effect of 5‑Fluorouracil.</p><p>&nbsp;</p><p>The onset of haemolytic uremic syndrome has been reported after long-term administration of 5-fluorouracil in combination with mitomycin.</p><p>&nbsp;</p><p>Incidents of cerebral infarction has been very rarely reported in conjunction with 5-fluorouracil therapy in combination with other chemotherapeutic agents (mitomycin&nbsp;C or cisplatin).</p><p>&nbsp;</p><p><u>General information</u></p><p>Cytostatic agents can reduce antibody formation following influenza vaccination.</p><p>Cytostatic agents can increase the risk of serious infection following the administration of live vaccines.</p><p>&nbsp;</p><p><u>Incompatibilities</u></p><p>5-fluorouracil may be diluted only with normal saline solution or 5% glucose solution.</p><p>5-fluorouracil must not be mixed in the same infusion as the other substances.</p><p>&nbsp;</p><p><u>Incompatibilities with the following substances have been reported:</u></p><p>cisplatin, cytarabine, diazepam, doxorubicin, droperidol, filgrastim, gallium nitrate, leucovorin, methotrexate, metoclopramide, morphine, ondansetron, parenteral nutrition solutions, vinorelbine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>5-fluorouracil can be mutagenic and must not be administered during pregnancy (see section 4.3). Women of childbearing age must ensure effective contraception during treatment and up to six months afterwards. If the patient becomes pregnant during treatment, genetic counselling should be taken into consideration.</p><p>&nbsp;</p><p>Animal studies revealed teratogenic reactions in foetuses.</p><p>&nbsp;</p><p>5-fluorouracil is suspected of causing severe damage to the unborn child if used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Since it is not known whether 5-fluorouracil passes into breast milk, women receiving this medicinal product must not breast-feed.If use during breast-feeding is essential, breast-feeding must be discontinued first (see section 4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>5-fluorouracil may cause genetic damage. Men treated with 5-fluorouracil are advised not to father a child during and for up to 6 months after the end of treatment. Advice on sperm conservation is recommended prior to treatment, because of the possibility of irreversible infertility due to therapy with 5-fluorouracil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5‑Fluorouracil may induce nausea, vomiting, undesirable reactions of the nervous system and visual changes which could indirectly interfere ability to drive or use machines. Therefore, do not drive or use machines during the treatment with 5‑Fluorouracil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common and serious undesirable effects of 5-fluorouracil are bone marrow toxicity and gastrointestinal symptoms.</p><p>&nbsp;</p><p>The following criteria are used for the frequency of undesirable effects:</p><p>&nbsp;</p><p>Very common (&ge; 1/10)</p><p>Common (&ge;1/100, &lt;1/10)</p><p>Uncommon (&ge;1/1,000, &lt;1/100)</p><p>Rare (&ge;1/10,000, &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data).</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Blood and lymphatic system disorders</strong></p><p><u>Very common:</u><em> </em>myelosuppression (leukopenia, neutropenia, thrombopenia), anaemia</p><p><u>Common:</u> febrile neutropenia</p><p><u>Very rare:</u> agranulocytosis, pancytopenia</p><p>&nbsp;</p><p><strong>Infections and infestations:</strong></p><p><u>Very common:</u> infections</p><p><u>Common:</u> immunosuppression with increased risk of infection</p><p><u>Rare:</u> sepsis</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Immune system disorders</strong></p><p><u>Rare</u>: general allergic reactions, anaphylaxis, anaphylactic shock</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Endocrine disorders</strong></p><p><u>Not known:</u><em> </em>total thyroxin (T<sub>4</sub>) and total triiodothyronine (T<sub>3</sub>) in the serum can increase, without increase of free T<sub>4</sub> and TSH, and without clinical signs of hyperthyroidism (patient thyroid levels remain clinically normal)</p><p>&nbsp;</p><p><strong>Metabolism and nutrition disorders</strong></p><p><u>Very common:</u> Hyperuricaemia</p><p>&nbsp;</p><p><strong>Psychiatric disorders</strong></p><p><u>Rare:</u> Confusion</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Nervous system disorders</strong></p><p><u>Uncommon:</u><em> </em>nystagmus, headache, dizziness, symptoms of Parkinson&rsquo;s disease, pyramidal signs, euphoria, somnolence</p><p><u>Rare:</u> peripheral neuropathy (in combination with radiotherapy)</p><p><u>Very rare:</u> dysgeusia, (leuko)encephalopathy with ataxia, acute cerebellar syndrome, speech disorders, dysarthria, confusion, disorientation, myasthenia, aphasia, convulsions, or coma</p><p><u>Not known:</u> hyperammonaemic encephalopathy</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Eye disorders</strong></p><p><u>Uncommon:</u> excessive lacrimation and lacrimal duct stenosis, blurred vision, eye movement disturbance, optic neuritis, double vision, decrease in visual acuity, photophobia, conjunctivitis, eyelid inflammation, ectropion due to scar formation and lacrimal gland fibroses</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Cardiac disorders</strong></p><p><u>Very common:</u> ischaemic ECG abnormalities</p><p><u>Common:</u> angina pectoris-like chest pain</p><p><u>Uncommon:</u><em> </em>arrhythmia, myocardial infarction, myocardial ischemia, myocarditis, cardiac insufficiency, dilative cardiomyopathy, cardiogenic shock</p><p><u>Very rare:</u><em> </em>cardiac arrest, sudden cardiac death;</p><p><u>Not known:</u> pericarditis</p><p><strong>&nbsp;</strong></p><p><strong>Vascular disorders</strong></p><p><u>Uncommon:</u> hypotension</p><p><u>Rare:</u> thrombophlebitis</p><p>Not known: cerebral, intestinal and peripheral ischaemia, Raynaud&#39;s syndrome, thromboembolism</p><p>&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p><u>Very common:</u> bronchial spasm, epistaxis</p><p>&nbsp;</p><p><strong>Gastrointestinal disorders</strong></p><p><u>Very common:</u><em> </em>gastrointestinal tract disorders (partially life-threatening), such as mucositis (stomatitis, pharyngitis, oesophagitis, proctitis), anorexia, (watery) diarrhoea, nausea, vomiting (see also section 4.4)<em> </em></p><p><u>Uncommon:</u><em> </em>dehydration, gastrointestinal ulceration and bleeding, sloughing</p><p>&nbsp;</p><p><strong>Hepatobiliary disorders</strong></p><p><u>Uncommon:</u> hepatic cell damage, non-calculous cholecystitis</p><p><u>Very rare:</u> infection (including fatal outcome)</p><p>&nbsp;</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><p><u>Very common:</u><em> </em>alopecia, palmar-plantar erythrodysaesthesia syndrome (&ldquo;hand-foot syndrome) with dysaesthesia, reddening, swelling, pain and scaling of the skin on palms and soles</p><p><u>Uncommon:</u><em> </em>dermatitis, skin alterations (dry skin, erosion/cracks, erythema, pruritic maculopapular rash), exanthema, urticaria, photosensitivity, hyperpigmentation of the skin, streaky hyperpigmentation or depigmentation in the vein area, changes in nails (e.g. diffuse superficial blue pigmentation, hyperpigmentation, nail dystrophy, pain and thickening of the nail bed paronychia) and onycholysis.</p><p>&nbsp;</p><p><strong>Reproductive system and breast disorders</strong></p><p><u>Uncommon:</u><em> </em>spermatogenesis and ovulation disorders</p><p><strong><u>&nbsp;</u></strong></p><p><strong>General disorders and administration site conditions</strong></p><p><u>Very common</u>: delayed wound healing, fatigue, general asthaenia, tiredness, listlessness, fever</p><p>&nbsp;</p><p><strong>Description of selected undesirable effects</strong></p><p><u>Blood and lymphatic system disorders</u></p><p>Myelosuppression is one of the dose-limiting undesirable effects (see also Section 4.2). The degree of severity (NCI grades I&ndash;IV) of myelosuppression depends on the method of administration (IV bolus injection or IV continuous infusion) and posology. Neutropenia occurs following each treatment cycle with an IV bolus injection with adequate doses (nadir: Days 9 &ndash; 14 &ndash; (20) of treatment; normal value: usually after day 30).</p><p>&nbsp;</p><p><u>Cardiac disorders</u></p><p>Cardiotoxic effects mostly occur during or within few hours of the first treatment cycle. There is an increased risk of cardiotoxicity in patients with previous coronary heart disease or cardiomyopathy.</p><p>&nbsp;</p><p><u>Gastrointestinal disorders</u></p><p>The degree of severity (NCI grade I&ndash;IV) of gastrointestinal undesirable effects depends on the posology and method of administration. In a continuous IV infusion, stomatitis is more likely than myelosuppression to be the dose limiting factor.</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>The hand-foot syndrome begins with dysaesthesia of the palms and soles that progress to reddening, swelling, pain, desquamation of the skin. It is <strong>very common </strong>after continuous IV administration and <strong>common </strong>after IV bolus injection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms of an overdose</u></p><p>The symptoms of overdose are increased occurrence of those symptoms mentioned under undesirable effects, such as nausea, vomiting, diarrhoea, severe mucositis, gastrointestinal ulcers and bleeding, bone marrow depression (thrombocytopenia, leukopenia, agranulocytosis).</p><p>&nbsp;</p><p>Acute:</p><p>psychotic reactions, somnolence, enhanced action of sedative drugs, increased alcohol toxicity.</p><p>&nbsp;</p><p>Should sedation be required, small doses (e.g. starting with 5 mg) of diazepam can be administered by IV, whilst monitoring the circulatory and respiratory system.</p><p>&nbsp;</p><p>Chronic:</p><p>bone marrow depression up to agranulocytosis and critical thrombopenia, bleeding tendency, gastrointestinal ulceration, diarrhoea and hair loss.</p><p>&nbsp;</p><p><u>Therapeutic measures</u></p><p>If symptoms of intoxication occur, 5-fluorouracil administration should be discontinued immediately. Measures for symptomatic treatment must be taken.</p><p>Infusions of leukocyte or platelet concentrate, infection prophylaxis. Forced diuresis to restore volume and mineral balance can be beneficial. In general, haemodialysis is not necessary. Careful monitoring to detect late-onset haematological and gastrointestinal complications on time.</p><p>Long-term myelosuppression must be treated under inpatient conditions. This includes, if necessary, substitution of missing blood components and antibiotic therapy. Transfer of the patient to an aseptic room might be necessary.</p><p>&nbsp;</p><p>Patients should be haematologically monitored for up to 4 weeks after an overdose.</p><p>&nbsp;</p><p>Should the therapy with 5-fluorouracil be continued despite the onset of cardiac undesirable effects, administration of vasodilators is indicated to prevent coronary artery spasms.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, Antimetabolites, Pyrimidine analogues, ATC code: L01BC02</p><p>&nbsp;</p><p>The antimetabolite 5-fluorouracil constitutes a fluorinated pyrimidine. 5-fluorouracil is enzymatically activated to deoxy-fluorouracil monophosphate. It inhibits the activity of thymidylate synthase and thus deoxythymidine monophosphate synthesis through complex formation. This results in phase-specific DNA-synthesis inhibition. Furthermore, deoxy-fluoro nucleotides inhibit de novo synthesis of pyrimidine nucleotides.</p><p>&nbsp;</p><p>Calcium folinate with 5-fluorouracil and thymidylate synthase forms a relatively stable ternary complex and thus prolongs the inhibiting action of 5-fluorouracil on thymidylate synthase. The result is the enhanced cytotoxic effect of 5-fluorouracil.</p><p>&nbsp;</p><p>5-fluorouracil has a phase-specific action in the cell cycle, particularly on the S-phase. The effect of the substance in rapidly proliferating tissue (bone marrow, skin and mucosa) is particularly pronounced.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5-FU is further catabolised by the enzyme DPD to the much less toxic dihydro-5-fluorouracil (FUH2). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureidopropionic acid (FUPA). Finally, &beta;-ureidopropionase cleaves FUPA to &alpha;-fluoro-&beta;-alanine (FBAL) which is cleared in the urine. Dihydropyrimidine dehydrogenase (DPD) activity is the rate limiting step. Deficiency of DPD may lead to increased toxicity of 5-fluorouracil (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>5-fluorouracil is only partially absorbed orally (0&ndash;80%).</p><p>&nbsp;</p><p>The substance exhibits a distribution of 0.12&nbsp;l/kg&nbsp;BW (following 15&nbsp;mg/kg&nbsp;BW IV) and can be found especially in rapidly proliferating tissue such as bone marrow, intestinal mucosa and neoplasia; 5-fluorouracil passes the blood-brain barrier.</p><p>&nbsp;</p><p>Metabolism takes place in the liver and is similar to uracil metabolisation. 5-fluorouracil is rapidly transformed enzymatically into the active metabolite dihydro-5-fluorouracil, which has a substantially longer half-life than 5-fluorouracil. Other non-toxic metabolites are carbon dioxide and urea.</p><p>&nbsp;</p><p>The plasma half-life (alpha phase) is between 8 and 22 minutes. The elimination half-life (beta phase) reaches approx. 20 hours due to the active metabolites in the tissue and is dose-dependent.</p><p>&nbsp;</p><p>5-fluorouracil (60&ndash;80%) is primarily exhaled by the lungs as carbon dioxide. 5‑Fluorouracil is secondarily excreted unchanged by the renal system (approx. 7&ndash;20%), approx. 90% of which is excreted within the first hour. The renal clearance is approximately 170&ndash;180&nbsp;ml/min. In impaired renal function, the substance is eliminated slowly.</p><p>&nbsp;</p><p>Maximum concentration in the cerebrospinal fluid is reached after approximately 1.5&ndash;2 hours and accounts for approx. 50% of plasma concentration.</p><p>&nbsp;</p><p>Kinetics in special clinical situations: despite the low proportion (approx. 15%) eliminated renally, an adequate dose adjustment is indicated depending on the degree of renal insufficiency and the reaction of the individual patient is indicated due to bone marrow impairment in azotaemia (due to renal insufficiency) and potential interference with the thrombocytes. A dose adjustment should also be taken into consideration in hepatic impairment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicity</u></p><p>The mitosis-inhibiting effect of 5-fluorouracil mainly affects rapidly proliferating tissues &ndash; both tumourigenic and healthy tissues. Accordingly, the toxicities are revealed particularly in bone marrow, with leukopenia, thrombocytopenia, gastrointestinal bleeding and secondarily in infections.</p><p>&nbsp;</p><p><u>Reproduction toxicity/mutagenicity/carcinogenicity</u></p><p>In different in-vitro cultures, fluorouracil shows mutagenic potential (various strains of salmonella typhimurium, micronucleus test on mice, at high concentrations chromosome strand damage in hamster fibroblasts). In vivo in male rats, chromosomal aberrations and altered spermatogenesis and even infertility were observed. In female rats, fluorouracil reduced fertility and induced chromosome aberrations in the embryos. The effects in rabbits were less substantial.</p><p>&nbsp;</p><p>Antimetabolites in animal studies showed carcinogenic properties. However, the risk of secondary tumours in humans seems to be lower than with alkylating substances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for injections and sodium hydroxide (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5-Fluorouracil Ebewe may be diluted only with normal saline solution or 5% glucose solution.</p><p>5-fluorouracil must not be mixed in the same infusion as the other substances.</p><p>&nbsp;</p><p>5-fluorouracil must not be diluted with strongly buffered solutions with pH &lt;8, since 5-fluorouracil precipitates in this environment. Do not mix with other chemotherapeutic solutions.</p><p>&nbsp;</p><p><u>Incompatibilities with the following active substances have been reported:</u></p><p>Fluorouracil is incompatible with folinic acid, carboplatin, cisplatin, cytarabine, diazepam, doxorubicin, droperidol, filgrastim, gallium nitrate, methotrexate, metoclopramide, morphine, ondansetron, parenteral nutrition, vinorelbine and other anthracyclines.</p><p>&nbsp;</p><p><u>Calcium folinate</u></p><p>Calcium folinate must not be mixed in the same infusion as 5-fluorouracil, because a precipitate may form. 5-fluorouracil 50 mg/ml with calcium folinate 20 mg/ml, with or without 5% dextrose in water, has been shown to be incompatible when mixed in different amounts and stored at 4&deg;C, 23&deg;C or 32&deg;C in polyvinyl chloride containers.</p><p>&nbsp;</p><p>5-Fluorouracil Ebewe solution for injection/infusion must not be mixed with other medicinal products, including oxaliplatin or irinotecan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p><p>Do not refrigerate or freeze.</p><p>Store in the original packaging to protect the contents from light.</p><p>&nbsp;</p><p>For single use only.</p><p>Use only clear and colourless to pale yellowish solutions.</p><p>&nbsp;</p><p>If precipitates have formed as a result of exposure to low temperatures, they can be dissolved by careful heating to 60&deg;C and shaking. Allow to cool before use.</p><p>&nbsp;</p><p><u>Shelf life after dilution</u></p><p>The product can be diluted with 0.9% sodium chloride solution or 5% glucose solution. Stability data in concentrations of 0.35 mg/ml and 15 mg/ml have shown that the maximum shelf life of ready-to-use 5-fluorouracil infusion solution is 28 days.</p><p>This shelf life refers both to refrigerator storage (2&deg;C&ndash;8&deg;C) including protection from light and storage at ambient temperature (20&deg;C&ndash;25&deg;C) with or without protection from light.</p><p>The chemical and physical stability of the prepared solution for infusion has been demonstrated for over 28 days. From a microbiological point of view, however, the ready-to-use solution for infusion should be used immediately. If it is not used immediately, the storage conditions for the ready-to-use solution for infusion before administration are the responsibility of the user and are normally no longer than 24 hours at 2&ndash;8&deg;C, except if the dilution is performed under controlled and validated aseptic conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1 / 5 vials with 5&nbsp;ml</p><p>1 / 5 vials with 10&nbsp;ml</p><p>1 / 5 vials with 20&nbsp;ml</p><p>1 vial with 100&nbsp;ml</p><p>&nbsp;</p><p>Type I amber glass vials with/without transparent PVC container (Onco-Safe).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the possible mutagenic and carcinogenic effects, enhanced safety precautions for hospital staff and physicians apply. While handling 5-fluorouracil, any contact with skin and mucosa should be avoided. Failing this, immediately wash with soap and water. In the event of eye contamination, rinse immediately with water and seek medical advice.All provisions must be made to allow for completely aseptic work. The use of a workspace with laminar flow is recommended. Protective clothing must be worn while handling 5-fluorouracil.</p><p>&nbsp;</p><p>Pregnant staff must not work with fluorouracil.</p><p>&nbsp;</p><p>Inactivation:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 700&deg;C</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium hypochlorite (bleach) diluted with 10 parts of water</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concentrated sodium hydroxide (NaOH) over several hours.</p><p>&nbsp;</p><p>The prepared solution should be used immediately after preparation.</p><p>Precipitates formed as a result of exposure to low temperatures can be dissolved by shaking and careful heating to 60&deg;C. Allow to cool prior to use.</p><p>&nbsp;</p><p>Loss of efficacy due to the adsorption of 5-fluorouracil in the glass infusion container has been described in the literature.</p><p>&nbsp;</p><p>The handling and disposal regulations for cytostatics must be observed.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBEWE Pharma Ges.m.b.H. Nfg. KG, 4866 Unterach, Austria


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>